Inventor · disambiguated record
Leila Marie Boustany
Also filed as: BOUSTANY LEILA M · BOUSTANY LEILA MARIE
8 granted patents·5 pending applications·75 citations·filing 2016–2023
87Inventor score
Top patents by PatentIndex Score
13 records- 0196US11859010B2Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2022·Granted Jan 2, 2024·5 cites·13 claims
- 0296US11814435B2Therapeutic antibodies and their usesPFIZER·Filed 2020·Granted Nov 14, 2023·5 cites·7 claims
- 0396US9969809B2Therapeutic antibodies and their usesPFIZER·Filed 2016·Granted May 15, 2018·44 cites·8 claims
- 0495US11155630B2Therapeutic antibodies and their usesPFIZER·Filed 2020·Granted Oct 26, 2021·3 cites·14 claims
- 0594US12460017B2Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2023·Granted Nov 4, 2025·1 cites·12 claims
- 0692US11472889B2Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Oct 18, 2022·7 cites·18 claims
- 0791US10793635B2Therapeutic antibodies and their usesPFIZER·Filed 2018·Granted Oct 6, 2020·4 cites·13 claims
- 0889US10040860B2Therapeutic antibodies and their usesPFIZER·Filed 2018·Granted Aug 7, 2018·6 cites·8 claims
- 0985US2024018252A1Therapeutic antibodies and their usesPFIZER·Filed 2023·Application pending·0 cites
- 1060US2025215110A1Activatable multispecific molecules and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1158US2025230239A1Cd3-binding proteins and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1258US2023174995A1Activatable polypeptide complexCYTOMX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1358US2023183382A1Activatable polypeptide complexCYTOMX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →